Quantcast

Latest BRCA1 Stories

2013-10-08 13:53:37

Technology as sensitive as standard methodology but more efficient, say researchers in the Journal of Molecular Diagnostics The recognition of a causal link between mutations in BRCA1 and BRCA2 genes and increased risk of developing breast and ovarian cancer has intensified the demand for genetic testing. Identifying mutations in these large genes by conventional methods can be time consuming and costly. A report in the November issue of the Journal of Molecular Diagnostics describes a new...

2013-10-07 23:25:11

A New York infertility treatment and research center earns a patent for a unique method of reducing the risk and spread of breast and ovarian cancer in women. New York, New York (PRWEB) October 07, 2013 The Center for Human Reproduction (CHR), a leading fertility research and treatment center in New York City, has been awarded a U.S. patent by the U.S. Patent and Trademark Office regarding use of FMR1 gene inhibitors as a method of reducing the risk of and/or spread of breast or ovarian...

2013-08-08 09:19:31

The global study was led by University of Melbourne and the Peter MacCallum Cancer Centre and published in the Journal of Clinical Oncology today. The study involved about 2,500 women from Europe, North America and Australia who have inherited mutations in BRCA1 or BRCA2, the breast cancer susceptibility genes, and who had been diagnosed with breast cancer. About one-third of these women were placed on tamoxifen. Tamoxifen has been used for decades to treat breast cancer and has...

2013-08-02 12:30:50

Two women have the same genetic mutation – an abnormal BRCA1 gene that puts them both at much higher-than-average risk for breast cancer – but only one woman develops the disease. Why? Michigan State University genetic scientists have begun to understand the mechanisms behind the phenomena. "It's been known for a while that genetic mutations can modify each other," explained Ian Dworkin, MSU associate professor of zoology. "And we also know that the...

2013-06-18 19:23:17

CNIO researchers take part in an international project that describes the molecular bases of resistance to a new chemotherapeutic agent in familial breast and ovarian cancers It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumors are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In patients with these mutations, PARP inhibitors, which are currently in clinical trials, have shown...

2013-06-14 23:15:49

Fulgent Therapeutics, a CLIA Certified Laboratory, announces today the inclusion of BRCA1 and BRCA2 analysis into its Hereditary Cancer Panel. Temple City, CA (PRWEB) June 14, 2013 Fulgent Therapeutics LLC, a CLIA Certified Laboratory, announces the inclusion of BRCA1 and BRCA2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets, making it the most comprehensive test for cancer risk assessment available. Fulgent Therapeutics Hereditary Cancer...

2013-06-13 23:03:37

Plaintiffs, including the American Civil Liberties Union, Association for Molecular Pathology, and American Society for Clinical Pathology, win long-fought case against Myriad Genetics, Association for Molecular Pathology v. Myriad Genetics, Inc. No. 12—398, that has far-reaching possibilities for genetic research and improved patient outcomes. Chicago, IL (PRWEB) June 13, 2013 The U.S. Supreme Court today invalidated patents on two genes associated with hereditary breast and ovarian...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related